---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-123925"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T17:35:57.174450+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acura secures $250K loan from AD Pharma, extends LTX-03 NDA deadline to March 2024, warns of possible bankruptcy

## Summary
- Received $250,000 loan from AD Pharma (owns ~66% of stock), bringing total debt to $4,669,279 at 5.25% interest, due Dec 31, 2023.
- If not repaid, default interest rises to 7.5%; company states without additional funding it will scale back or cease operations.
- Amended LTX-03 development deal: FDA NDA acceptance deadline extended to March 31, 2024; AD Pharma can terminate anytime.
- If NDA not accepted by March 31, 2024, AD Pharma may take over LTX-03 intellectual property.
- AD Pharma, controlled by John Schutte, also holds warrants for 10M shares; Schutte directly owns ~14% of Acura.

## SEC filing metadata
- accession: 0001104659-23-123925
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465923123925/0001104659-23-123925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465923123925/tm2332252d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-123925
- JSON: https://secwatch.observer/filing/0001104659-23-123925.json
- Plain text: https://secwatch.observer/filing/0001104659-23-123925.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $250,000 loan with Abuse Deterrent Pharma, LLC at 5.25% maturing December 31, 2023.
  - Instrument: loan
  - Principal: $250,000 loan
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: December 31, 2023
  - Event: incurrence
  source text: On December 4, 2023 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now totals $4,669,279, bears interest at 5.25% and matures on December 31, 2023, at which time all principal and interest is due (“Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465923123925/0001104659-23-123925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.